Yarrow Bioscience, Inc. Common Stock
YARW
98 hedge funds and large institutions have $138M invested in Yarrow Bioscience, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 16 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 21
1% more funds holding
Funds holding: 97 → 98 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
5% more capital invested
Capital invested by funds: $132M → $138M (+$6.25M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.74M |
| 2 |
DAM
Deltec Asset Management
New York
|
+$3.66M |
| 3 |
Two Sigma Investments
New York
|
+$1.05M |
| 4 |
Squarepoint
New York
|
+$873K |
| 5 |
State Street
Boston,
Massachusetts
|
+$867K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.54M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$581K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$352K |
| 4 |
Morgan Stanley
New York
|
-$276K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$258K |
YARW Hedge Fund Activity: Q4 2020 in Review
98 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q4 2020, worth a combined $138M — up 4.7% from $132M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new YARW positions and 16 closed out — a net gain of 1 holder — while 33 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $3.74M. The largest seller was Vivo Capital, cutting an estimated $1.54M.
- 98 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q4 2020, up from 97 in Q3 2020.
- Funds reported $138M of Yarrow Bioscience, Inc. Common Stock stock for Q4 2020, up 4.7% quarter-over-quarter.
- 17 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q4 2020 and 16 closed out, a net change of +1 holder.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q4 2020 was BlackRock, an estimated $3.74M added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q4 2020 was Vivo Capital, an estimated $1.54M sold.
Based on aggregated 13F filings for Q4 2020.